Mankind Pharma vs Zydus Lifesciences: Share Price, Valuation and Results Compared

Mankind Pharma (NSE: MANKIND) and Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) are both listed in the Medicinal Chemicals and Botanical Products industry. Mankind Pharma has a market capitalisation of ₹1,09,870 Cr and Zydus Lifesciences ₹1,19,651 Cr, as of 16 Nov 2026. Their P/E ratios are 57 and 24.1 respectively. Return on equity is 12.45% for Mankind Pharma and 18.32% for Zydus Lifesciences. Over one year, Mankind Pharma's share price is up 16.7% and Zydus Lifesciences's is up 26.0%.

Mankind Pharma vs Zydus Lifesciences — Key Figures

MetricMankind PharmaZydus Lifesciences
NSE SymbolMANKINDZYDUSLIFE
BSE Code543904532321
Share Price₹2,640.00₹1,189.90
Market Cap₹1,09,870 Cr₹1,19,651 Cr
P/E Ratio5724.1
Return on Equity12.45%18.32%
Return on Assets6.31%8.13%
Dividend Yield0.08%0.08%
Beta (1Y)0.370.26
1-Year Price Change+16.7%+26.0%
3-Month Price Change+9.8%+1.9%
52-Week Range₹1,909.70 – ₹2,705.00₹835.50 – ₹1,266.60
Latest QuarterQ2 FY27Q2 FY27
Quarterly Revenue₹4,338 Cr₹7,910 Cr
Quarterly Net Profit₹716 Cr₹928 Cr
Net Margin16.5%11.7%
EPS (Basic, Quarter)₹17.23₹9.28
Results Basisconsolidatedconsolidated
HeadquartersNew Delhi, DelhiAhmedabad, Gujarat

The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.

About the Companies

Mankind Pharma

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations…

Zydus Lifesciences Ltd

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of onco…

Frequently Asked Questions

Which is larger by market cap, Mankind Pharma or Zydus Lifesciences?

Zydus Lifesciences has a market capitalisation of ₹1,19,651 Cr, against ₹1,09,870 Cr for Mankind Pharma as of 16 Nov 2026, so the two are about the same size by market cap.

What is the P/E ratio of Mankind Pharma and Zydus Lifesciences?

Mankind Pharma has a P/E of 57 and Zydus Lifesciences a P/E of 24.1 as of 16 Nov 2026.

What is the return on equity of Mankind Pharma and Zydus Lifesciences?

Mankind Pharma has a return on equity of 12.45% and Zydus Lifesciences 18.32%.

How have Mankind Pharma and Zydus Lifesciences shares moved over one year?

Mankind Pharma's share price is up 16.7% over one year and Zydus Lifesciences's is up 26.0%.

What were the latest quarterly results of Mankind Pharma and Zydus Lifesciences?

Mankind Pharma reported revenue of ₹4,338 Cr and net profit of ₹716 Cr for Q2 FY27. Zydus Lifesciences reported revenue of ₹7,910 Cr and net profit of ₹928 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.

Which industry are Mankind Pharma and Zydus Lifesciences in?

Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.

Is this comparison a recommendation to buy or sell Mankind Pharma or Zydus Lifesciences?

No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.

More Comparisons

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.